Results 131 to 140 of about 4,836 (184)

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, Burzi L, Castelli F, Chiarpenello M, Graziola F, Leporati C, Ortoncelli M, Pella P, Pertusi G, Pisterna A, Quaglino P, Ribero S, Rossotto G, Tiberio R, Dapavo P, Savoia P.   +20 more
europepmc   +1 more source

Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review. [PDF]

Medicine (Baltimore)
Afzal MW, Haseeb A, Ali U, Ashraf MR, Mehmood A, Perveen A.   +5 more
europepmc   +1 more source

Safety of Biologic Therapy for Inflammatory Bowel Disease in Liver Transplant Recipients. [PDF]

Biomedicines
Elger T, Loibl J, Müller M, Rusch S, Baier-Kleinhenz L, Kandulski A, Buechler C, Tews HC.   +7 more
europepmc   +1 more source

The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study. [PDF]

An Bras Dermatol
Pehlivan Ulutaş G, Özkök Akbulut T, Polat Ekinci A.   +2 more
europepmc   +1 more source

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Hsu CC, Huang YH, Tsai TF.
europepmc   +1 more source

Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab. [PDF]

Crohns Colitis 360
Han J, Puangampai A, Man B, Kandah HM, Rubin DT, Choi DK.   +5 more
europepmc   +1 more source

Expanding treatment frontiers in hidradenitis suppurativa: Double immunomodulator therapy in severe refractory cases. [PDF]

JAAD Case Rep
Tolete C, Friedman A, Duong T, Tjahjono L.   +3 more
europepmc   +1 more source

Factors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea. [PDF]

Ann Dermatol
Choi MS, Yeom K, Jung SW, Hong SP, Kong KA, Kim MH.   +5 more
europepmc   +1 more source

Safety of Risankizumab during Pregnancy in IBD. [PDF]

Inflamm Bowel Dis
Tsur N, Ben Ya'acov A, Ungar B, Ron Y, Avni-Biron I, Reiss Mintz H, Koslowsky B, Mishael T, Bar Gil Shitrit A.   +8 more
europepmc   +1 more source